Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Ireland are on track to lift virus restrictions on May 4 - Varadkar

Thu, 15th Apr 2021 13:10

(Alliance News) - Ireland is on track to lift coronavirus restrictions from May 4, Tanaiste Leo Varadkar has said.

The deputy prime minister also said that 80% of the population will have had their first dose of Covid vaccine, or have been offered it, by the end of June.

He said the Dublin government will sit down at the end of April to develop a reopening plan for the months of May, June and July.

The government is planning for more outdoor activities, a phased reopening of retail and the return of personal services such as hairdressers on a staggered basis next month.

He said: "For the first time this year, the number of people in hospitals is below 200 and the number in ICU below 50.

"Cases are stable or falling, the R number is below one. Kids are back to school, the five kilometre rule is gone, we're building houses again.

"We are on track, we're on track both to ease restrictions as planned from May 4, and to have over 80% of people receiving their first vaccine by the end of June."

Asked if he is sure about the June vaccination target given the issues with the rollout to date, Varadkar replied: "They'll have it in their arm or they'll certainly have been offered it at that stage. It's as solid as it can be."

Varadkar told RTE's Morning Ireland the situation is "looking good", but that things can still go wrong.

He said reopening will depend on four key indicators: "vaccines, variants, case numbers and the state of our hospitals".

He said: "What we'll do in about two weeks' time at the end of April, is we'll sit down and develop the plan for May.

"What we're planning is allowing more outdoor activities, a phase reopening of retail and personal services.

"Over the course of the month of May there will be a phased reopening of personal services including hairdressers and barbers.

"What we'll also do at the end of April, that's not far away now, we'll develop the plan for June and July."

Varadkar also said that people will not be allowed to choose which vaccine they receive.

It comes after a recommendation from the National Immunisation Advisory Committee that the AstraZeneca PLC vaccine is only given to people over the age of 60.

Varadkar said the advice should not undermine confidence in the safety of the vaccine.

He said: "The best option is the vaccine that's offered to you. All the vaccines are effective and they're safe for the age groups they're indicated for."

He said if a person refuses to have the AstraZeneca jab, they will have to "wait until the end" of the rollout to be given a vaccine.

"It's not possible to know when the end would be, but it wouldn't be June or July, it would be later than that," he added.

The HSE launched a new online vaccines portal where people can register for the inoculations on Thursday. It is currently open to people aged between 65 and 69.

The government has said it is examining extending the intervals between the two doses of AstraZeneca to speed up the vaccine programme, as has been done in the UK.

Studies have shown people are still given high levels of immunity, over 80%, from a single dose.

But Varadkar said on Thursday that people who have already received their first dose will still get their second as planned.

"We're not going to change it for them," he said. "They've even been given the date at this stage, and they're also the people who are generally the highest risk, so it makes sense to fully protect them."

He said that if longer intervals between doses are introduced, it will only be for younger people who do not have any medical vulnerabilities.

By James Ward, PA

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.